460 Studies Now Enrolling
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of High Systemic Inflammation
A study for patients with ALS using study drug NP001
| Sponsor: | Neuraltus Pharmaceuticals, Inc. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ6200 |
| U.S. Govt. ID: | NCT02794857 |
| Contact: | Jinsy Andrews: 212-342-3022 / ja2289@cumc.columbia.edu |
Additional Study Information:
The purpose of this research study is to test an investigational drug called NP001. The study will evaluate if NP001 has an effect on slowing the signs and symptoms of your ALS, if there are any side effects, and if there are any medical problems with giving the drug as a solution into your vein (intravenous IV administration). An investigational drug is one that has not been approved by the Food and Drug Administration (FDA) but is allowed to be used for research. NP001 is for research use only. In this study one half of patients will get NP001, the other half will get placebo, which will look the same but does not contain NP001. Therefore, you have a 1 in 2 chance of getting NP001.
This study is closed
